# British and Irish Hypertension Society response to ‘RAAS inhibitors in pregnancy, breastfeeding and women of childbearing potential: a review of national and international clinical practice guidelines’

## TL;DR

The British and Irish Hypertension Society responds to a review on RAAS inhibitors, emphasizing the need for clearer guidance for women of childbearing age.

## Contribution

The paper provides a focused response and highlights key clinical considerations and research gaps for RAAS inhibitors in women.

## Key findings

- RAAS inhibitors require careful consideration in women of childbearing potential due to potential fetal risks.
- Current guidelines lack explicit advice on RAAS inhibitor use during pregnancy and breastfeeding.
- Further research is needed to guide clinicians in managing hypertension in this population.

## Abstract

In their review of clinical practice guidelines on the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, Greenlees and Delles call for more explicit advice on the use of these drugs among women of childbearing potential, during pregnancy and breastfeeding. In response, the British and Irish Hypertension Society (BIHS) highlight the key issues for clinicians to consider when prescribing RAAS inhibitors to hypertensive women and suggest areas where further research is needed.